April 25, 2017
Belleville, Ontario – NovaVive Inc., a Canadian immunobiology company, today announced that its cattle immunotherapeutic – Amplimune™ – is now available to Canadian veterinarians. The product recently received approval from the Canadian regulatory authority (CFIA). The product is also approved for sale in the U.S.
Amplimune is a potent immunomodulator that reduces the clinical signs and mortality associated with E. coli K99 diarrhea in neonatal calves. The product is an emulsion of mycobacterium cell wall fractions (MCWF) that enhances innate immunity to fight bacterial infections without the use of antibiotics. The product can be administered by intravenous, intramuscular or subcutaneous injection.
Veterinarians and cattle producers are under increasing pressure to reduce antibiotic therapies used in animals, particularly food producing animals like cattle. E. coli diarrhea in calves is typically treated with antibiotics.
There is a growing concern in Canada and globally about the dramatic increase of antibiotic resistance. In animals, this has primarily resulted from the indiscriminate use or overuse of antibiotics as preventative therapies or growth promoters. “The development of antimicrobial-resistant pathogens in animals can pose serious risks to human health when they are transmitted as food-borne or water-borne contaminants. Antimicrobial-resistant infections are associated with a greater risk of death, more complex illnesses, longer hospital stays and higher treatment costs.” (Health Canada)
“There is a growing need for effective antibiotic alternatives,” said Graeme McRae, President of NovaVive Inc. “Products like Amplimune that activate the body’s innate immune system to fight infection and disease are one such alternative. We are excited to be taking this proactive step to help Canadian cattle producers curb antibiotic use in their herds, and we look forward to working with producers and veterinarians to assess additional cattle diseases where antibiotic alternatives are needed.”
There are approximately 960,000 dairy cattle and approximately 3.8 million beef cattle in Canada (producing 3.9 million calves per year) (Statistics Canada).
About NovaVive Inc.
NovaVive is a private company founded in July, 2014. The Company has an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction technology with 4 regulator-approved products. Certain formulations have demonstrated the capability of reducing the reliance on antibiotics in the treatment of diseases of horses and cattle. Other formulations have been developed as anticancer therapies in dogs and horses and as a respiratory disease treatment for horses. The Company’s development plan is to identify additional livestock and companion animal diseases that may be effectively treated with its immunotherapeutic technology platform.
For more information about the Company, please visit www.NovaVive.ca , or contact:
Graeme McRae, President
Jennifer Shea, V-P, Investor Relations & Business Development
7 September 2017 - Belleville, Ontario – NovaVive Inc., an animal health immunobiology company, is pleased to announce...
May 5 - Belleville, Ontario – NovaVive Inc., an animal health immunobiology company, is pleased to announce that it is...
Belleville, Ontario – NovaVive Inc., a Canadian immunobiology company, today announced that its cattle immunotherapeutic...
Graeme McRae, Founder and Chairman Emeritus of Bioniche Life Sciences Inc., has founded NovaVive Inc., a Belleville,...